In gemcitabine‐resistant pancreatic cancer cells, METTL14 is regulated by P65, a transcriptional factor binding to METTL14 promoter region, and elevates the transcript stability of CDA, which causes gemcitabine inactivation, and ultimately developments gemcitabine resistance of pancreatic cancer cells in vitro and in vivo.48 This evidence concerns the gene CDA and pancreatic neoplasm.